Allianz Asset Management Gmb H Akebia Therapeutics, Inc. Transaction History

Allianz Asset Management Gmb H

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$4.1 - $10.24 $243,667 - $608,573	-59,431 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$3.16 - $6.73 $187,801 - $399,970	59,431 New	59,431 $376,000
Q3 2018 Nov 13, 2018	SELL	$7.44 - $10.65 $922,024 - $1.32 Million	-123,928 Closed	0 $0
Q2 2018 Aug 13, 2018	SELL	$9.15 - $11.34 $6,313 - $7,824	-690 Reduced 0.55%	123,928 $1.24 Million
Q1 2018 May 14, 2018	BUY	$9.53 - $15.68 $1.19 Million - $1.95 Million	124,618 New	124,618 $1.19 Million
Q4 2017 Feb 13, 2018	SELL	$14.24 - $19.59 $675,545 - $929,349	-47,440 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$13.06 - $19.67 $619,566 - $933,144	47,440	47,440 $933,000

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.